About: Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT
Creator	Scambia, Giovanni Colloca, Giuseppe Gambacorta, Maria Tagliaferri, Luca Tamburrini, Enrica Corrado, Giacomo Fagotti, Anna Garganese, Giorgia Gentileschi, Stefano Lancellotta, Valentina Macchia, Gabriella Can, Vul Fragomeni, Maria Gemelli, · Simona, ·
Source	Medline; PMC
abstract	INTRODUCTION: Since the community spread of Coronavirus disease 2019 (COVID-19), the practice of oncologic care at our comprehensive cancer center has changed. Postponing cancer treatment without consideration of its implications could cost more lives than can be saved. In this special situation, we must continue to provide our cancer patients with the highest quality of medical services assuring the safety. This article provides general guidance on supporting curative treatment strategies in vulvar cancer patients. METHODS: At our institution, a vulvar cancer multidisciplinary team (Vul.Can MDT) of specialists is responsible for personalized treatment of this disease. The phase 2 period necessarily requires specific procedures for both outpatient and inpatient pathways and to provide strategies concerning the management of vulvar cancer patients even in case of an eventually concomitant SARS-CoV-2 infection. In brief, an accurate remote and in person triage must be provided routinely and patients submitted to specific diagnostic tests prior to every major treatment or procedure (surgery, RT, and CT) or in case of suspicion for COVID-19 syndrome. The decisional workflow for these women often old and frail, have been rapidly adjusted by our Vul.Can MDT to mitigate the potential risks of COVID-19. RESULTS: The team produced two types of recommendations concerning: (1) safety regulations of care pathways, patients and health care providers, (2) personalized treatment strategies. We present a protocol that can be applied in clinical practice: the flowcharts provided, include the modulation of treatment intensity designed for surgical procedures and radiation, stratified for FIGO stage of disease and intention. CONCLUSION: We suggest that our proposals are applicable in this setting of patients, considering anyway current international recommendations and guidelines.
has issue date	2020-07-12(xsd:dateTime)
bibo:doi	10.1007/s00432-020-03312-9
bibo:pmid	32656663
has license	no-cc
sha1sum (hex)	3a11b35cdbcb6349a1262e36407f5814b26506d2
schema:url	https://doi.org/10.1007/s00432-020-03312-9
resource representing a document's title	Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT
has PubMed Central identifier	PMC7354358
has PubMed identifier	32656663
schema:publication	J Cancer Res Clin Oncol
resource representing a document's body	covid:3a11b35cdbcb6349a1262e36407f5814b26506d2#body_text
is schema:about of	named entity 'curative' named entity 'workflow' named entity 'cancer' named entity 'multidisciplinary team' named entity 'Cancer Research' covid:arg/3a11b35cdbcb6349a1262e36407f5814b26506d2 named entity 'services' named entity 'surgery' named entity 'serologic tests' named entity 'clinical presentation' named entity 'COVID' named entity 'early diagnosis' named entity 'Montana' named entity 'metastasis' named entity 'plastic surgery' named entity 'surgical resection' named entity 'COVID-19' named entity 'cutaneous' named entity 'medical conditions' named entity 'tumor' named entity 'oncologist' named entity 'radiotherapy' named entity 'lymph nodes' named entity 'extent of disease' named entity 'vulvar cancer' named entity 'lesion' named entity 'nasopharyngeal swab' named entity 'gynecologist' named entity 'phase 2' named entity 'article' named entity 'COVID' named entity 'risk factors' named entity 'inguinal lymph node' named entity 'pauci' named entity 'metabolic' named entity 'anti-cancer treatments' named entity 'morbidity' named entity 'diffusion' named entity 'infection' named entity 'chemotherapy' named entity 'outpatient' named entity 'ultrasound' named entity 'vulvar carcinoma' named entity 'advanced stages' named entity 'anti-cancer treatments' named entity 'medical oncologist' named entity 'radiation therapy' named entity 'palliative care' named entity 'symptoms and signs' named entity 'MRI' named entity 'viral infection' named entity 'clinical care' named entity 'ultrasound' named entity 'tumor' named entity 'Oncological' named entity 'ultrasound' named entity 'vulvar cancer' named entity 'debulking' named entity 'Flowchart' named entity 'laboratory tests' named entity 'oncological' named entity 'SARS-CoV-2' named entity 'immunosuppressed' named entity 'mitigate' named entity 'community spread' named entity 'medical services' named entity 'diagnostic tests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software